 |
|
|
| |
Tobevibart (VIR-3434) and Elebsiran (VIR-2218) With or Without
Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection:
End of Treatment Results After 48 Weeks of Therapy (MARCH Study)
|
| |
| |
AASLD 2024 Nov 15-19 San Diego
Edward Gane,1 Kosh Agarwal,2 Jeong Heo,3 Alina Jucov,4 Young-Suk Lim,5 Anca Streinu-Cercel,6 Grace Wong,7 Ki Tae Yoon,8
Andre Arizpe,9 Keith Boundy,9 Shuli Yu,9 Li Wang,9 Karen Tracy,9 Andrea L. Cathcart,9 Todd Correll,9 Carey Hwang,9 Man-Fung Yuen10
|
| |
|
|
|
|
|
